Prelude Therapeutics Incorporated Common Stock PRLD
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T00:47:06.498Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:00.420888381Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T00:44:53.960011+00:00
Prelude Therapeutics Incorporated Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | 4.62 | 201.2% | 30.9% | |||
| 40Δ | 4.45 | 198.1% | 28.4% | |||
| 45Δ | 4.28 | 195.1% | 25.9% | |||
| 50Δ | 4.10 | 192.1% | 23.4% | |||
| 55Δ | 3.93 | 189.1% | 20.9% | |||
| 60Δ | 3.75 | 186.1% | 18.4% | |||
| 65Δ | 3.58 | 183.0% | 15.9% | |||
| 70Δ | 3.40 | 180.0% | 13.5% | |||
| 75Δ | 3.23 | 177.0% | 11.0% | |||
| 80Δ | 3.06 | 174.0% | 8.5% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 4.62
- IV
- 201.2%
- B/E move
- 30.9%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 4.45
- IV
- 198.1%
- B/E move
- 28.4%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 4.28
- IV
- 195.1%
- B/E move
- 25.9%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 4.10
- IV
- 192.1%
- B/E move
- 23.4%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 3.93
- IV
- 189.1%
- B/E move
- 20.9%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 3.75
- IV
- 186.1%
- B/E move
- 18.4%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 3.58
- IV
- 183.0%
- B/E move
- 15.9%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 3.40
- IV
- 180.0%
- B/E move
- 13.5%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 3.23
- IV
- 177.0%
- B/E move
- 11.0%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 3.06
- IV
- 174.0%
- B/E move
- 8.5%
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
PRME
Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology, which enables precise DNA…
More →PROK
ProKidney Corporation. The company is headquartered in Winston-Salem, North Carolina.
More →PRQR
ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders. The company is…
More →PRTA
Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases in the United States. The…
More →PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. The company is…
More →PTGX
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is…
More →